Side effects of Ozempic, what to actually expect.

How common are they, really?

Ozempic has the longest safety record of any GLP-1 agonist: more than 25,000 randomised patients across the SUSTAIN, STEP and SELECT trial programmes. The side-effect profile is well-characterised, dose-dependent, and almost entirely gastrointestinal. The number worth anchoring on isn't the nausea rate — it's the discontinuation rate.

In STEP-1 (Wilding, NEJM 2021), 89.7% of the semaglutide group reported at least one adverse event — but so did 86.4% of the placebo group. The gap is narrower than headlines suggest. Most "Ozempic side effects" you hear about are background life events. The drug-attributable share is concentrated in the gut. And of that share, 4.5% of semaglutide patients stopped treatment because of GI events, versus 0.8% on placebo. The other 95.5% rode it out.

The cleanest tolerability dataset is the pooled STEP 1–3 analysis (Wharton, Diabetes Obes Metab 2022): 99.5% of GI adverse events were non-serious, and 98.1% were mild or moderate. Median duration of a nausea episode was 8 days, diarrhoea 3 days, vomiting 2 days. The hardest stretch is roughly week 2 to week 8, peaking after each dose increase, then plateauing. For the molecule itself, see our semaglutide guide.

Very common (more than 1 in 10).

Six effects fall into the "very common" bucket. The frequencies below are from STEP-1's 2.4 mg semaglutide arm against placebo, except where noted. The good news, repeated because it matters: these are nearly all mild-to-moderate, dose-titration-driven, and self-limiting.

Common (1 in 100 to 1 in 10).

Hair thinning deserves a specific note. In the Wegovy adolescent trial, it reached 4% versus 0% on placebo; a 2025 real-world cohort reported an adjusted hazard ratio of 2.08 in women relative to bupropion-naltrexone. The mechanism is telogen effluvium driven by rapid weight loss, not direct follicle toxicity, and it is almost always reversible within 3–6 months once weight stabilises.

Uncommon and rare.

Acute pancreatitis — uncommon, under 1%

Pooled data across SUSTAIN, STEP and SELECT show pancreatitis rates statistically indistinguishable from placebo. In STEP-1, three semaglutide patients (0.2%) versus zero on placebo developed mild acute pancreatitis. In SELECT (Lincoff, NEJM 2023, n=17,604), the two arms were equivalent. The boxed concern persists because of mechanism, not high incidence. The presentation to know is severe upper-abdominal pain radiating to the back, with or without vomiting. Stop the pen, go to emergency, ask for a serum lipase.

Gallbladder disease — uncommon, around 2–3%

SELECT reported gallbladder disorders in 2.8% on semaglutide vs 2.3% on placebo (p=0.04), driven by cholelithiasis (1.4% vs 1.1%); cholecystitis was equal at 0.6% in both arms. STEP-1 showed 2.6% vs 1.2%. Important context: rapid weight loss itself promotes gallstones — semaglutide is partially a marker for the risk, not solely its cause.

Diabetic retinopathy worsening — uncommon, in diabetics only

SUSTAIN-6 (Marso, NEJM 2016) found retinopathy complications in 3.0% on semaglutide vs 1.8% on placebo (HR 1.76; 95% CI 1.11–2.78; p=0.02). 83.5% of affected patients had pre-existing retinopathy. The driver appears to be the speed of HbA1c reduction, not a direct drug effect. If you have diabetes, get a dilated retinal exam before starting and again at six months.

NAION (a vision complication) — rare

The Hathaway study (JAMA Ophthalmology, 2024) reported a hazard ratio of 4.28 for non-arteritic anterior ischaemic optic neuropathy in patients with diabetes, with 36-month cumulative incidence of 8.9% vs 1.8%. These are relative numbers from a single-centre neuro-ophthalmology referral cohort with significant selection bias. A larger Danish cohort and a multi-database study (2025) found a much smaller HR of 2.22, with absolute incidence around 0.026% vs 0.017%. The takeaway: the absolute risk is low, but sudden painless vision loss in one eye is an emergency — stop the injection and see an ophthalmologist the same day.

Allergic reactions — rare

Anaphylaxis and angioedema are listed in the post-marketing section of the Ozempic label with no estimable frequency. Local injection-site rash is more common.

Thyroid C-cell tumours — boxed warning, rodent-only signal

Semaglutide produces dose-dependent thyroid C-cell tumours in rats. No causal signal has been established in humans across the SUSTAIN, STEP or SELECT programmes; a 2024 systematic review (n=14,550 across 10 RCTs) found thyroid cancer incidence under 1% and no significant excess versus controls. Despite this, it remains an absolute contraindication if you or a first-degree relative has medullary thyroid carcinoma or MEN-2 syndrome.

"Ozempic face" — and how to avoid it.

"Ozempic face" is the dermatology term for the gaunt, deflated look that follows rapid facial fat loss. It is not a unique pharmacological effect of semaglutide — it is what happens to any face when you lose 15% of your body weight in six months. The buccal and temporal fat pads thin out faster than skin can retract, and the result reads as ten years older overnight.

Prevention is entirely mechanical. Aim for 0.5–1% body weight loss per week, not more. Resistance-train three days a week to preserve lean mass and muscle volume in the face and neck. Hit 1.2–1.6 g of protein per kg per day. Do not skip the maintenance phase. None of this requires fillers; it requires patience.

Managing GI side effects, the practical playbook.

This is the protocol Kaivo doctors give every patient at week one. None of it is novel, but the sequencing matters — most patients who quit Ozempic at week 6 regret it by month 6, and they almost always quit because no one walked them through the basics.

1. Stay on each dose for at least four weeks. Most nausea is escalation-driven. If 0.5 mg feels rough, hold for eight weeks before stepping up to 1 mg. There is no medal for fast titration.
2. Inject at night, before bed. You sleep through the peak plasma rise on day 2–3, which is when nausea is worst.
3. Half-portions and no fried food for 72 hours after each injection. Skip the besan-heavy items, the deep-fried snacks, the full-cream dairy, and the biryani with extra ghee until the wave passes.
4. Protein first, then vegetables, then carbs. Eating in this order keeps satiety high on smaller volumes and reduces post-meal reflux.
5. 2.5–3 litres of fluid daily. Plain water plus one sachet of ORS on hot days and on diarrhoea days.
6. Start isabgol 1 tbsp at bedtime from week two. Prevent constipation before it starts — treating it after the fact is much harder.
7. Domperidone 10 mg or ondansetron 4 mg as rescue. Only with your doctor's prescription, and only on the worst days. Not prophylactically.
8. Track everything for 12 weeks. The first two months are the hardest. Most patients stabilise after that and forget the medication is even in them.

“The side effect patients in our Delhi and Bangalore clinics worry about most is nausea, and the side effect that almost always resolves on its own is nausea. Of the patients who tell me at week 3 they want to stop, more than 80% are perfectly comfortable at week 10 if we simply hold the dose. The first two months are the hardest; after that, most patients stabilise and forget the medication is even in them.”
Dr Rinku Sarmah · Clinical Lead, Kaivo

Pregnancy and fertility, what every woman needs to know.

Stop Ozempic at least two months (8 weeks) before any planned conception. This is the explicit Novo Nordisk and FDA label instruction, based on semaglutide's half-life of about one week and the "five half-lives for complete clearance" rule. Animal studies in rats, rabbits and cynomolgus monkeys showed embryo-fetal toxicity, growth restriction and skeletal abnormalities at clinically relevant exposures; human data remain limited.

If you have PCOS, expect cycles to regularise faster than feels possible. Weight loss of 5–10% often restores ovulation — this is the so-called "Ozempic baby" phenomenon. Use reliable contraception throughout treatment for two reasons: you may ovulate before you expect to, and delayed gastric emptying can reduce oral contraceptive absorption in the first few weeks.

Breastfeeding: avoid semaglutide. Rat lactation studies showed transfer to milk at 3–12 fold lower than maternal plasma, but human safety data are absent.

9 red flags. Stop and call today.

The vast majority of patients never see any of these. But if you do, none of them is wait-and-watch. Stop the injection and call your prescriber or go to the nearest A&E.

1. Severe, persistent abdominal pain radiating to the back. Possible pancreatitis.
2. Sudden painless vision loss in one eye, or a dark patch in your visual field. Possible NAION.
3. Vomiting more than six times in 24 hours, or inability to keep fluids down. Dehydration and electrolyte risk.
4. Right-upper-quadrant pain with fever, jaundice or pale stools. Possible cholecystitis or gallstones.
5. A new lump or swelling in the neck, hoarseness, or trouble swallowing. Thyroid evaluation needed urgently.
6. Black, tarry or bloody stools, or coffee-ground vomiting. GI bleeding.
7. Swelling of face, lips, tongue or throat; difficulty breathing; widespread rash. Allergic reaction — go to A&E.
8. Reduced urine output for 24 hours, or dark concentrated urine with confusion. Acute kidney injury from dehydration.
9. A positive pregnancy test while on Ozempic. Stop immediately and call your prescriber.

What this means for you.

If you're about to start your first 0.25 mg dose

Your odds of significant nausea on the starter dose are roughly 1 in 4, not 1 in 2 — the 44% figure is the cumulative rate across 68 weeks at the full 2.4 mg dose. Inject on a Sunday night, eat half-portions Monday and Tuesday, keep an ORS sachet handy. If you feel nothing, don't panic. About 55% of patients sail through week 1 with no symptoms at all.

If you're at week 6 and struggling with persistent nausea

Do not escalate the dose. Hold at your current strength for another four weeks. Add domperidone before meals, switch to a bland Indian diet (khichdi, curd-rice, idli, steamed vegetables) for two weeks, and review with your doctor. Week 6 has the highest regret rate of any drop-off point — almost everyone who pushes through is comfortable by week 10.

If you're considering pregnancy in the next 12 months

Plan backwards. To conceive in January, stop Ozempic by November at the latest. Use barrier contraception or a non-hormonal IUD during the washout. If you have PCOS, expect cycles to regularise faster than you expect — don't assume infertility while in the washout window.

Indian-context, practical management.

Summer dehydration, April through June

GI side effects compound with 40°C+ heat in ways the STEP trials never tested. Carry one ORS sachet (Electral or WHO-formula, ~₹25) in your bag from March onwards. Tender coconut water — one glass delivers around 250 mg of potassium for about ₹40 — replaces electrolytes better than plain water on vomiting days. Nimbu pani with a pinch of salt and a pinch of sugar is a free home substitute. Avoid sugary aerated drinks; they worsen osmotic diarrhoea.

Vegetarian protein during nausea windows

Hitting 1.2 g/kg of protein on a vegetarian Indian diet while nauseous is the single hardest thing for our patients. Anchor numbers worth memorising: paneer 100 g = 18 g protein, moong or toor dal one katori (~150 g cooked) = 7 g, dahi 200 g = 7 g, two eggs = 12 g, soya chunks 30 g dry = 16 g, whey isolate one scoop = 24 g. A 65 kg woman targeting 78 g/day can hit it with: one scoop whey in the morning, 100 g paneer at lunch, one katori dal plus 200 g dahi at dinner, 30 g roasted chana as a snack.

Festival and fasting calendars

Diwali, Eid, Karva Chauth, Navratri and Ramadan all collide with titration schedules. Two rules. First, never inject the night before a heavy feast — push the dose to the morning after, with your doctor's sign-off. Second, for day-long fasts, drop your dose by one tier that week (for example, 1 mg → 0.5 mg) to avoid hypoglycaemia and dehydration, then resume normal titration the following week. For longer Ramadan-style fasts, plan injection timing for after iftar.

References.

1. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1). NEJM 2021;384:989–1002.
2. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). NEJM 2016;375:1834–1844.
3. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). NEJM 2023;389:2221–2232.
4. Hathaway JT et al. Risk of NAION in patients prescribed semaglutide. JAMA Ophthalmol 2024;142(8):732–739.
5. Wharton S et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity. Diabetes Obes Metab 2022.
6. Ozempic Prescribing Information, Novo Nordisk, 2025 edition.

This article is for educational purposes only and does not constitute medical advice. Ozempic (semaglutide) is a prescription medication (Schedule H in India). Always consult a qualified healthcare professional before starting, stopping, or changing any treatment. Reviewed by Dr Rinku Sarmah, MBBS, MD (Internal Medicine), AIIMS-trained physician and Clinical Lead at Kaivo.